ArticleMolecular biology reports2026
Investigation of the effects of desvenlafaxine on pro-inflammatory cytokine production in LPS-stimulated macrophage cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDesvenlafaxine, a serotonin–norepinephrine reuptake inhibitor (SNRI) used for major depressive disorder, is the primary active metabolite of venlafaxine. While the immunomodulatory effects of the parent compound, venlafaxine, are well-documented, the direct impact of desvenlafaxine on macrophage-mediated inflammation remains less understood. This study aims to investigate whether desvenlafaxine influences pro-inflammatory cytokine production in activated macrophages.
methodsJ774.2 macrophages were stimulated with lipopolysaccharide (LPS) to induce an inflammatory response and treated with desvenlafaxine at concentrations of 1, 5, and 10 µg/mL. Cell viability was assessed to ensure non-toxic dosing, and the concentrations of pro-inflammatory cytokines, including TNF-α, IL-6, IL-12p40, and GM-CSF, were quantified using Enzyme-Linked Immunosorbent Assay (ELISA).
resultsOur results indicate that desvenlafaxine significantly inhibits the secretion of TNF-α and IL-6 in a concentration-dependent manner without affecting cell viability. Notably, IL-12p40 levels showed a significant reduction primarily at the lowest concentration (1 µg/mL). These findings suggest a selective anti-inflammatory effect on key macrophage-derived mediators under the tested conditions.
conclusionsOur findings suggest that desvenlafaxine possesses potential immunomodulatory properties by modulating pro-inflammatory cytokine release. This study provides preliminary evidence that its therapeutic benefits in depression may involve neuroinflammatory pathways beyond classical neurotransmission, although further research is required to clarify the underlying mechanisms.
Indexed as
Identifiers
42012755What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.